2023-08-31 13:22:00
For almost a year now, the supply of medicines is complicated in France. Paracetamol, antibiotics… The risks of shortages have multiplied, forcing the government to take action.
Among them, the creation of a list of essential medicines, with in particular the relocation of some of them. Still with the aim of providing the French with the necessary treatments, the State has just announced the rise in the price of amoxicillinthe best-selling antibiotic in France.
Amoxicillin: an agreement offered to 13 pharmaceutical companies
Amoxicillin is used: “in the treatment of various infectious diseases, in particular of the nose, throat, ears, lungs, bronchi, urinary system, joints and teeth”, explains Vidal, reference site for health products. Widely used, it was mainly targeted by the risk of shortages at the end of 2022.
Thus, to allow all French people to be able to obtain it without fear, the government has just proposed an agreement to manufacturers. As TF1 reports, the state authorizes a 10% increase in the price of amoxicillin. In exchange, the 13 laboratories concerned will be “required to provide a sufficient quantity of drugs to ensure the supply of France”. If they do not respect their agreement, they will be obliged to repay the surplus collected thanks to the price increase.
Concretely, what does this change for the patient? TF1 details by giving the following example: “Here is the consequence for patients: today, a box of 14 tablets costs 5.89 euros. It is reimbursed at 65% by health insurance. The patient therefore pays 2.06 euros. Next October, this amount will increase to 2.29 euros“.
Biogaran has already accepted the offer
For its part, the Biogaran laboratory has already accepted the offer. “We signed in mid-August with the Economic Committee for Health Products an agreement which aims to provide a framework for this agreement“, explains to BFMTV Rémy Petitot, the head of the public affairs company of the pharmaceutical company. Thus, the laboratory will provide nearly 13 million boxes, or 13% more than last year.
Medicines: soon a price increase extended to other treatments?
This unprecedented deal in France aims to avoid reproducing the situation experienced by France last winter. However, as Rémy Petitot explains, this decision came a little late: “This agreement was put in place in July for the winter while our production schedules are already established“.
Plus, the lab’s Public Affairs manager would like this to spread to other drugs. Questioned by TF1, Jérôme Wirotius, CEO of Biogaran, adds: “We hope that this increase is only the beginning. We have 150 drugson our catalog of 1000 drugs, on which we lose money. These must be upgraded as a matter of priority”. If this test proves to be positive, it might be extended to other treatments in the coming months.
1693517180
#price #increase #France
